[eLD2] Navigating Health Disparities in Sickle Cell Disease from a Payer Perspective

August 27, 2024

Pricing: Free for Members and Non-Members

This activity is supported by an independent medical education grant from Vertex Pharmaceuticals. 

Program Description

Sickle cell disease is considered an orphan disease, affecting less than 200,000 individuals in the U.S., yet is the most prevalent and well-known inherited disease. The value potential of gene therapies, particularly for serious or life-threatening rare diseases, is realized in long-term outcomes, durable cures, and single administration. With the recent FDA approval of two transformative gene therapies in December 2023, the potential to significantly decrease overall health care costs by reducing healthcare utilization and the expenses associated with managing sickle cell disease throughout a patient's lifetime emerges. However, the novelty and treatment complexities associated with gene therapy generate concerns about equitable access, particularly with the high investment cost.  

Target Audience

This knowledge-based activity has been designed to meet the educational needs of pharmacists in managed care settings. 

Learning Objectives

At the completion of this program, participants should be able to:

  1. Describe the chronic progression and complications of sickle cell disease contributing to its overall disease burden.
  2. Recognize the racial health disparities impacting access to care and treatment advances for the sickle cell disease community.
  3. Review current and pipeline treatments, including efficacy, safety, durability, and clinical utilization of emerging gene therapies for sickle cell disease.
  4. Identify innovative payment model strategies to enhance sickle cell disease health outcomes, expand treatment options, and optimize health care utilization.
Course summary
Available credit: 
  • 1.00 ACPE
    ACPE The Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
  • 1.00 Certificate of Completion
Course opens: 
06/27/2024
Course expires: 
09/23/2024
Event starts: 
08/27/2024 - 1:00pm EDT
Event ends: 
08/27/2024 - 2:00pm EDT
Cost:
$0.00
Part of: 
eLearning Day August 2024
Add to calendar: 

Speakers:


Andrew Campbell, MD
Director of Comprehensive Sickle Cell Program
Children's National Medical Center
Associate Professor of Pediatrics
George Washington University School of Medicine



Angela Luong, PharmD
Senior Clinical Consultant
Pharmacy Strategies Group (PSG)

 


Emily Tsiao, PharmD, BCPS
Medical Policies Clinical Pharmacist
Premera Blue Cross

ACPE UAN: 0233-0000-24-031-L01-P
Activity Type: Knowledge-Based
Contact Hours: 1
Release Date: June 27, 2024
Expiration Date: September 23, 2024
Activity Fee: Free for Members and Non-Members

CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your NABP account.

To receive credit for an online activity you must:

  • Review the full content of the activity.
  • Successfully complete the post-test (required to pass with a score of 70% or higher).
  • Complete a specific activity evaluation.

Available Credit

  • 1.00 ACPE
    ACPE The Academy of Managed Care Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
  • 1.00 Certificate of Completion

Price

Cost:
$0.00
Please login or register to take this course.